## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  JOHNSON DAVID EDWARD						2. Issuer Name and Ticker or Trading Symbol EXELIXIS, INC. [ EXEL ]								(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 05/31/2023									Officer (give title below)						
515 MADISON AVENUE 8TH FLOOR					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person					
(Street) NEW YORK NY 10022						X Form filed by More than One Reporting Person														
(City)	(5	(State) (Zip)				Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	ole I - No	n-Deriv	vative	Se	curitie	s Ac	quired,	Dis	posed o	f, oı	r Ben	eficial	y Owned	i				
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day)					r)   ! r)   i	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired Disposed Of (D) (Instr. 5)		d (A) or r. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				/2022(2	222(2)		Code	v	Amount	Amount (A) or (D) Pr		Price \$0	(Instr. 3 and 4)		D <sup>(3)</sup>					
Common Stock <sup>(1)</sup> 05/31/20 Common Stock					2023	23(4)			A		10,17	U A		Ψ0	910,730		I		See footnote <sup>(4)</sup>	
		7	Table II -												Owned		<u> </u>		Toomote	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed 4. Execution Date, if any C		4. Transac Code (In 8)	tion	n of E		6. Date Exercisal Expiration Date (Month/Day/Year		able and	7. Title and Amount of Securities Underlying Derivative S (Instr. 3 and		Security d 4)	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Beneficie Owned Followin Reported Transact (Instr. 4)	ve es ially ng d tion(s)	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
					Code			Date Exercisabl		Expiration Date	Title		Amount or Number of Shares							
Option (right to buy)	\$19.28	05/31/2023					36,353		05/31/2023	05/30/20		Common Stock		36,353	\$0 36,3		53	D <sup>(3)</sup>		
		f Reporting Person* VID EDWAR																		
(Last) (First) (Middle) 515 MADISON AVENUE 8TH FLOOR																				
(Street) NEW YORK NY 10022																				
(City)	(City) (State) (Zip)																			
Name and Address of Reporting Person*     Caligan Partners LP																				
(Last) (First) (Middle) 515 MADISON AVENUE 8TH FLOOR																				
(Street) NEW YORK NY 10022																				

### **Explanation of Responses:**

(State)

(Zip)

(City)

- 2. The restricted stock units were granted to Mr. Johnson on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on each of the first four anniversaries of the Transaction Date, subject to the Mr. Johnson's continuous service through such dates.
- 3. Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Fund and the Caligan Accounts.
- 4. Reflects securities held by the Caligan Fund and the Caligan Accounts. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
- 5. Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date, subject to Mr. Johnson's continuous service through such dates.

#### Remarks:

Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Caligan may be deemed to be a director by deputization of the Issuer by virtue of the fact that Mr. Johnson currently serves on the Issuer's board of directors.

/s/ David Edward Johnson 06/02/2023
Caligan Partners LP, By: /s/

<u>David Johnson, Managing</u> <u>Partner</u>

06/02/2023

tt Cianatum

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.